Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer

摘要: The recent approval of two PD-1 inhibitors for the treatment non-small cell lung cancer (NSCLC) has rapidly led to widespread use these agents in oncology practices. Pneumonitis been recognized as a potentially life-threatening adverse event among NSCLC patients treated with inhibitors; however, detailed clinical and radiographic manifestations this entity remain be described. We report on cases anti-PD-1 pneumonitis advanced nivolumab after its FDA approval. Both presented ground-glass reticular opacities consolidations peripheral distribution CT, demonstrating pattern cryptogenic organizing pneumonia. Consolidations were extensive developed within 8 weeks therapy both cases. corticosteroids subsequent improvement respiratory symptoms findings. One patient experienced recurrent completing corticosteroid taper, or "pneumonitis flare," absence retreatment, upon readministration. With increasing immune checkpoint growing number tumor types, awareness inhibitor-related will critical prompt diagnosis management serious event.